Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry
2019 ◽
Vol 70
(1)
◽
pp. e113-e114
◽
2019 ◽
Vol 114
(1)
◽
pp. S599-S600
2008 ◽
Vol 27
(9)
◽
pp. 790-797
◽
2016 ◽
Vol 64
(2)
◽
pp. S218-S219
◽